Skip to main content

Advertisement

SpringerLink
Log in

Does cyclooxygenase-2 affect blood pressure?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

With the development and clinical implementation of the new cyclooxygenase (COX)-2 inhibitors, their safety, including the effects on renal function and blood pressure, is attracting increasing attention. In the kidney, COX-2 is constitutively expressed and is highly regulated in response to alterations in intravascular volume. COX-2 metabolites have been implicated in mediation of renin release, regulation of sodium excretion, and maintenance of renal blood flow. Similar to conventional nonsteroidal anti-inflammatory drugs, inhibition of COX-2 may cause modest elevations in blood pressure in a minority of subjects. COX-2 inhibitors may also exacerbate pre-existing hypertension or interfere with other antihypertensive drugs. Special caution should be taken in patients with volume depletion or decreased organ perfusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lipsky PE: Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol 1999, 26(Suppl 56):25–30.

    Google Scholar 

  2. Xie WL, Chipman JG, Robertson DL, et al.: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991, 88:2692–2696.

    Article  PubMed  CAS  Google Scholar 

  3. Tazawa R, Xu XM, Wu KK, Wang LH: Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994, 203:190–199.

    Article  PubMed  CAS  Google Scholar 

  4. Komhoff M, Grone HJ, Klein T, et al.: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272:F460-F468.

    PubMed  CAS  Google Scholar 

  5. Harris RC, McKanna JA, Akai Y, et al.: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504–2510.

    PubMed  CAS  Google Scholar 

  6. Cheng HF, Wang JL, Zhang MZ, et al.: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest 2000, 106:681–688.

    PubMed  CAS  Google Scholar 

  7. Nantel F, Meadows E, Denis D, et al.: Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999, 457:475–477.

    Article  PubMed  CAS  Google Scholar 

  8. Yang T, Singh I, Pham H, et al.: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998, 274:F481–489.

    PubMed  CAS  Google Scholar 

  9. Cheng HF, Wang JL, Zhang MZ, et al.: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999, 103:953–961.

    PubMed  CAS  Google Scholar 

  10. Traynor TR, Smart A, Briggs JP, Schnermann J: Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999, 277:F706–710.

    PubMed  CAS  Google Scholar 

  11. Kammerl MC, Nusing RM, Richthammer W, et al.: Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001, 60:1684–1691.

    Article  PubMed  CAS  Google Scholar 

  12. Cheng HF, Wang JL, Zhang MZ, et al.: Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001, 280:F449–456.

    PubMed  CAS  Google Scholar 

  13. Yang T, Endo Y, Huang YG, et al.: Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000, 279:F819–825.

    PubMed  CAS  Google Scholar 

  14. Athirakul K, Kim HS, Audoly LP, et al.: Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001, 60:2324–2329.

    Article  PubMed  CAS  Google Scholar 

  15. Khan KN, Stanfield KM, Harris RK, Baron DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail 2001, 23:321–330.

    Article  CAS  Google Scholar 

  16. Komhoff M, Jeck ND, Seyberth HW, et al.: Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000, 58:2420–2424.

    Article  PubMed  CAS  Google Scholar 

  17. Kammerl MC, Nusing RM, Schweda F, et al.: Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. Clin Pharmacol Ther 2001, 70:468–474.

    PubMed  CAS  Google Scholar 

  18. Stichtenoth DO, Wagner B, Frolich JC: Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med 1998, 46:290–296.

    PubMed  CAS  Google Scholar 

  19. Reinalter SC, Jeck N, Brochhausen C, et al.: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002, 62:253–260.

    Article  PubMed  CAS  Google Scholar 

  20. Harris RC Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002, 89:10D-17D.

    Article  PubMed  CAS  Google Scholar 

  21. Harris RC, Breyer MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001, 281:F1–11.

    PubMed  CAS  Google Scholar 

  22. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension 1999, 34:1163–1167.

    PubMed  CAS  Google Scholar 

  23. Lopez-Parra M, Claria J, Planaguma A, et al.: Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002, 135:891–900.

    Article  PubMed  CAS  Google Scholar 

  24. Vio CP, Cespedes C, Gallardo P, Masferrer JL: Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997, 30:687–692.

    PubMed  CAS  Google Scholar 

  25. Rodriguez F, Llinas MT, Gonzalez JD, et al.: Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000, 36:276–281.

    PubMed  CAS  Google Scholar 

  26. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 2000, 56:383–388.

    Article  PubMed  CAS  Google Scholar 

  27. Rossat J, Maillard M, Nussberger J, et al.: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76–84.

    Article  PubMed  CAS  Google Scholar 

  28. Catella-Lawson F, McAdam B, Morrison BW, et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999, 289:735–741.

    PubMed  CAS  Google Scholar 

  29. Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465–1470.

    Article  PubMed  CAS  Google Scholar 

  30. McAdam BF, Catella-Lawson F, Mardini IA, et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999, 96:272–277.

    Article  PubMed  CAS  Google Scholar 

  31. Komers R, Lindsley JN, Oyama TT, et al.: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001, 107:889–898.

    Article  PubMed  CAS  Google Scholar 

  32. Kistler T, Ambuhl PM: Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med Wkly 2001, 131:193–198.

    PubMed  CAS  Google Scholar 

  33. Chen BH: COX-2 inhibitors and renal function in elderly people. Can Med Assoc J 2000, 163:604.

    CAS  Google Scholar 

  34. Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000, 133:1–9.

    PubMed  CAS  Google Scholar 

  35. Ahmad SR, Kortepeter C, Brinker A, et al.: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002, 25:537–544.

    Article  PubMed  CAS  Google Scholar 

  36. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.

    PubMed  CAS  Google Scholar 

  37. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477–484.

    Article  PubMed  CAS  Google Scholar 

  38. Nusing RM, Reinalter SC, Peters M, et al.: Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 2001, 70:384–390.

    PubMed  CAS  Google Scholar 

  39. Wang JL, Cheng HF, Harris RC: Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999, 34:96–101.

    PubMed  CAS  Google Scholar 

  40. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247–1255. The CLASS Study was a double-blind, randomized control trial conducted from September 1998 to March 2000 to compare the effect and safety of celecoxib versus NSAIDs for osteoarthritis and rheumatoid arthritis.

    Article  PubMed  CAS  Google Scholar 

  41. Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001, 21:1–15.

    Article  PubMed  CAS  Google Scholar 

  42. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106–2111.

    Article  PubMed  CAS  Google Scholar 

  43. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520–1528. The VIGOR study was a large double-blind, randomized, controlled trial to study the effect and safety of rofecoxib versus NSAIDs in rheumatoid arthritis.

    Article  PubMed  CAS  Google Scholar 

  44. FDA Arthritis Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_01_merck.pdf. Accessed December 2001.

  45. Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000, 7:159–175.

    Article  PubMed  CAS  Google Scholar 

  46. Collantes E, Curtis SP, Lee KW, et al.: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002, 3:10.

    Article  PubMed  Google Scholar 

  47. White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929–934. This is a very recent randomized, double-blind, placebo-controlled, parallel-group clinical trial to investigate the effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.

    Article  PubMed  CAS  Google Scholar 

  48. Whelton A: Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001, 110(Suppl 3A):33S-42S.

    Article  PubMed  CAS  Google Scholar 

  49. Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, 26(Suppl 56):18–24.

    Google Scholar 

  50. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, S 3223 MCN, Vanderbilt University School of Medicine, 37232-2372, Nashville, TN, USA

    Hui-Fang Cheng MD & Raymond C. Harris MD

Authors
  1. Hui-Fang Cheng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond C. Harris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, HF., Harris, R.C. Does cyclooxygenase-2 affect blood pressure?. Current Science Inc 5, 87–92 (2003). https://doi.org/10.1007/s11906-003-0016-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0016-y

Keywords

Search

Navigation